Impaired lipoprotein processing in hiv patients on antiretroviral therapy aberrant high-density lipoprotein lipids, stability, and function

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 7, 2013, Pages 1714-1721

  Gillard, Baiba K ^a,c   Raya, Joe L ^a,b   Ruiz Esponda, Raul ^a,b   Iyer, Dinakar ^a,b   Coraza, Ivonne ^a,b,d   Balasubramanyam, Ashok ^a,b   Pownall, Henry J ^a,c,d  

^a Department of Medicine   (United States)

^b Diabetes Research Center   (United Kingdom)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Hepatocyte Cholesteryl Ester Uptake; High Density Lipoprotein Function; Hiv Dyslipidemia; Lipoprotein Composition

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FREEZING; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPOLIPEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; VALIDATION STUDY;

HEPATOCYTE CHOLESTERYL ESTER UPTAKE; HIGH-DENSITY LIPOPROTEIN FUNCTION; HIV DYSLIPIDEMIA; LIPOPROTEIN COMPOSITION;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CHOLESTEROL ESTERS; COMBINED MODALITY THERAPY; DIET; EXERCISE; FIBRIC ACIDS; HEPATOCYTES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; NIACIN; PROTEIN STABILITY; RECEPTORS, LIPOPROTEIN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84879083921     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301538     Document Type: Article

References (38)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
2. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-330.
3. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Møller N; Writing Committee of the D:A:D: Study Group. Cardio-and cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811-1817.
4. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med. 1999;131:548.
5. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
6. Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J. 2004;147:55-59.
7. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007;30:113-119.
8. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79-86.
9. Tong Q, Sankalé JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab. 2003;88:1559-1564.
10. Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
11. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC, Sharma M, Reeds PJ, Balasubramanyam A. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab. 2002;283:E332-E337.
12. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism. 2002;51:1143-1147.
13. Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab. 2003;285:E490-E497.
14. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4:e365.
15. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol. 2011;22:176-185.
16. Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, Taylor AA, Giordano TP, Sekhar RV, Clark P, Cuevas-Sanchez E, Kamble S, Ballantyne CM, Pownall HJ. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96:2236-2247.
17. Shen BW, Scanu AM, Kézdy FJ. Structure of human serum lipoproteins inferred from compositional analysis. Proc Natl Acad Sci U S A. 1977;74:837-841.
18. Mehta R, Gantz DL, Gursky O. Human plasma high-density lipoproteins are stabilized by kinetic factors. J Mol Biol. 2003;328:183-192.
19. Pownall HJ, Hosken BD, Gillard BK, Higgins CL, Lin HY, Massey JB. Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning. Biochemistry. 2007;46:7449-7459.
20. Gillard BK, Rosales C, Pillai BK, Lin HY, Courtney HS, Pownall HJ. Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol. Biochemistry. 2010;49:9866-9873.
21. Rosales C, Gillard BK, Courtney HS, Blanco-Vaca F, Pownall HJ. Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. Biochemistry. 2009;48:8070-8076.
22. Gillard BK, Courtney HS, Massey JB, Pownall HJ. Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. Biochemistry. 2007;46:12968-12978.
23. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
24. Pownall HJ, Brauchi D, Kilinç C, Osmundsen K, Pao Q, Payton-Ross C, Gotto AM Jr., Ballantyne CM. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-297.
25. Aragonès G, Beltrán-Debón R, Rull A, Rodríguez-Sanabria F, Fernández-Sender L, Camps J, Joven J, Alonso-Villaverde C. Human immunodeficiency virus-infection induces major changes in highdensity lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. Clin Chem Lab Med. 2010;48:1147-1152.
26. Yarasheski KE, Tebas P, Claxton S, Marin D, Coleman T, Powderly WG, Semenkovich CF. Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol Endocrinol Metab. 2003;285:E899-E905.
27. Singaraja RR, Sivapalaratnam S, Hovingh K, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on highdensity lipoprotein levels and functionality in humans. Circ Cardiovasc Genet. 2013;6:54-62.
28. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119:1042-1050.
29. Silver ET, Scraba DG, Ryan RO. Lipid transfer particleinduced transformation of human high density lipoprotein into apolipoprotein A-I-deficient low density particles. J Biol Chem. 1990;265:22487-22492.
30. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J. 1996;313:275-282.
31. Liang HQ, Rye KA, Barter PJ. Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase. J Lipid Res. 1996;37:1962-1970.
32. Rye KA, Hime NJ, Barter PJ. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem. 1997;272:3953-3960.
33. Nichols AV, Gong EL, Blanche PJ, Forte TM, Anderson DW. Effects of guanidine hydrochloride on human plasma high density lipoproteins. Biochim Biophys Acta. 1976;446:226-239.
34. Rosseneu M, Van Tornout P, Lievens MJ, Schmitz G, Assmann G. Dissociation of apolipoprotein AI from apoprotein-lipid complexes and from high-density lipoproteins. A fluorescence study. Eur J Biochem. 1982;128:455-460.
35. Rosales C, Tang D, Gillard BK, Courtney HS, Pownall HJ. Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo. Arterioscler Thromb Vasc Biol. 2011;31:1834-1841.
36. Baril L, Beucler I, Valantin MA, Bruckert E, Bonnefont-Rousselot D, Coutellier A, Caumes E, Katlama C, Bricaire F. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS. 2001;15:415-417.
37. Johnston CS, Kim CM, Buller AJ. Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes. Diabetes Care. 2004;27:281-282.
38. Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transport. In: Bondy PK, Rosenberg LE, eds. The Metabolic Control of Disease. Philadephia, PA; Saunders Publishing; 1980:398-494.